Alvotech: Main Results of 2025 Annual and Extraordinary General Meeting

June 25, 2025 | Last Trade: US$5.12 0.03 -0.58

REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.

All of the draft resolutions on the 2025 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company’s special web portal for the 2025 Annual General Meeting at: https://investors.alvotech.com/corporate-governance/annual-general-meeting-2025

Alvotech Investor Relations

Benedikt Stefansson
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$5.12
Daily Change:	-0.03 -0.58
Daily Volume:	339,974
Market Cap:	US$1.600B

November 24, 2025 Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area November 20, 2025 Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) November 12, 2025 Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update November 06, 2025 Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA November 02, 2025 Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 LOAD MORE NEWS

Featured Stock

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE